Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/40673
Title: A retrospective, multicenter study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real-world setting in Belgium
Authors: Nasreddine, Rakan
Florence, Eric
Yombi, Jean Cyr
Henrard, Sophie
Darcis, Gilles
Van Praet, Jens
Vandekerckhove, Linos
Allard, Sabine
Demeester, Rémy
MESSIAEN, Peter 
Ausselet, Nathalie
Delforge, Marc
De Wit, Stéphane
Corporate Authors: Belgian Research on AIDS and HIV Consortium (BREACH)
Issue Date: 2022
Source: HIV Glasgow, Glasgow, 23 – 26 October 2022
Abstract: Conclusion • Several RCTs have demonstrated BIC/FTC/TAF to be a first-line option for treatment-naïve and experienced PLWH [1-4]. • Real-world studies provide complementary information to RCTs and ensure that those results can be generalized to broader populations seen in daily practice. • The aim of this study was to describe the Belgian HIV population treated with BIC/FTC/TAF and to evaluate its efficacy, durability, and tolerability in a real-world setting.
Document URI: http://hdl.handle.net/1942/40673
Category: C2
Type: Conference Material
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
poster 9 PowerPoint Presentation.pdfConference material943.06 kBAdobe PDFView/Open
Show full item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.